Literature DB >> 8932772

Plasmodium yoelii: peptide immunization induces protective CD4+ T cells against a previously unrecognized cryptic epitope of the circumsporozoite protein.

Y Takita-Sonoda1, M Tsuji, K Kamboj, R S Nussenzweig, P Clavijo, F Zavala.   

Abstract

In this study we characterized the CD4+ T cell response directed against two distinct epitopes located in the circumsporozoite (CS) protein of Plasmodium yoelii. The immunization of mice with P. yoelii sporozoites induced CD4+ T cells which were mostly directed against one of these peptides, Py-1, previously reported to contain a CD4+ epitope. The CD4+ T cells directed against this immunodominant epitope were mostly of the Th-1 type. Another newly identified peptide, AS44, induced a specific CD4+ T cell response, which was mainly detectable after immunization with the corresponding peptide. Several CD4+ T cell clones, recognizing this epitope, were generated and their lymphokine expression was characterized, as well as their surface markers and their anti-parasite activity in vivo. It was noteworthy that some of these CD4+ T cell clones, which recognize this cryptic epitope and were of different Th subtypes, were shown to have a strong inhibitory effect on the development of liver stages of malaria parasites.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8932772     DOI: 10.1006/expr.1996.0108

Source DB:  PubMed          Journal:  Exp Parasitol        ISSN: 0014-4894            Impact factor:   2.011


  10 in total

1.  A subdominant CD8(+) cytotoxic T lymphocyte (CTL) epitope from the Plasmodium yoelii circumsporozoite protein induces CTLs that eliminate infected hepatocytes from culture.

Authors:  E D Franke; A Sette; J Sacci; S Southwood; G Corradin; S L Hoffman
Journal:  Infect Immun       Date:  2000-06       Impact factor: 3.441

2.  Complete, long-lasting protection against malaria of mice primed and boosted with two distinct viral vectors expressing the same plasmodial antigen.

Authors:  O Bruña-Romero; G González-Aseguinolaza; J C Hafalla; M Tsuji; R S Nussenzweig
Journal:  Proc Natl Acad Sci U S A       Date:  2001-09-11       Impact factor: 11.205

3.  The Toxoplasma gondii peptide AS15 elicits CD4 T cells that can control parasite burden.

Authors:  Harshita Satija Grover; Nicolas Blanchard; Federico Gonzalez; Shiao Chan; Ellen A Robey; Nilabh Shastri
Journal:  Infect Immun       Date:  2012-07-09       Impact factor: 3.441

4.  A potent malaria vaccine based on adenovirus with dual modifications at Hexon and pVII.

Authors:  Takayuki Shiratsuchi; Urvashi Rai; Izumi Kaneko; Min Zhang; Shiroh Iwanaga; Masao Yuda; Moriya Tsuji
Journal:  Vaccine       Date:  2017-10-28       Impact factor: 3.641

Review 5.  A retrospective evaluation of the role of T cells in the development of malaria vaccine.

Authors:  Moriya Tsuji
Journal:  Exp Parasitol       Date:  2009-11-26       Impact factor: 2.011

Review 6.  T cell-mediated immunity to malaria.

Authors:  Noah S Butler; John T Harty; Samarchith P Kurup
Journal:  Nat Rev Immunol       Date:  2019-07       Impact factor: 53.106

7.  Interferon-γ, a valuable surrogate marker of Plasmodium falciparum pre-erythrocytic stages protective immunity.

Authors:  Blanca-Liliana Perlaza; Jean-Pierre Sauzet; Karima Brahimi; Lbachir BenMohamed; Pierre Druilhe
Journal:  Malar J       Date:  2011-02-08       Impact factor: 2.979

8.  Antigen targeting to dendritic cells elicits long-lived T cell help for antibody responses.

Authors:  Silvia B Boscardin; Julius C R Hafalla; Revati F Masilamani; Alice O Kamphorst; Henry A Zebroski; Urvashi Rai; Alexandre Morrot; Fidel Zavala; Ralph M Steinman; Ruth S Nussenzweig; Michel C Nussenzweig
Journal:  J Exp Med       Date:  2006-02-27       Impact factor: 14.307

Review 9.  CD4 T-cell subsets in malaria: TH1/TH2 revisited.

Authors:  Damian Perez-Mazliah; Jean Langhorne
Journal:  Front Immunol       Date:  2015-01-12       Impact factor: 7.561

Review 10.  Vaccination With Sporozoites: Models and Correlates of Protection.

Authors:  Yun Shan Goh; Daniel McGuire; Laurent Rénia
Journal:  Front Immunol       Date:  2019-06-05       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.